Ionis Pharmaceuticals (NASDAQ:IONS) Receives Buy Rating from Needham & Company LLC
Needham & Company LLC restated their buy rating on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) in a research report report published on Friday morning, Benzinga reports. Needham & Company LLC currently has a $60.00 price objective on the stock. IONS has been the subject of a number of other research reports. Morgan Stanley […]
More Stories
Columbia Sportswear (NASDAQ:COLM) Issues Q3 Earnings Guidance
Columbia Sportswear (NASDAQ:COLM – Get Free Report) issued an update on its third quarter earnings guidance on Thursday morning. The...
Boston Beer (NYSE:SAM) Announces Quarterly Earnings Results
Boston Beer (NYSE:SAM – Get Free Report) posted its quarterly earnings data on Thursday. The company reported $4.39 earnings per...
Bitcoin Gold Market Cap Tops $457.42 Million (BTG)
Bitcoin Gold (BTG) traded up 4.7% against the dollar during the 1-day period ending at 22:00 PM Eastern on July...
AbbVie (NYSE:ABBV) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS
AbbVie (NYSE:ABBV – Get Free Report) posted its earnings results on Thursday. The company reported $2.65 EPS for the quarter,...
Bluzelle (BLZ) Trading 8.7% Lower Over Last Week
Bluzelle (BLZ) traded up 1% against the U.S. dollar during the one day period ending at 22:00 PM E.T. on...
Bitcoin Diamond (BCD) Tops 24-Hour Volume of $4,433.51
Bitcoin Diamond (BCD) traded 10.4% higher against the dollar during the twenty-four hour period ending at 22:00 PM Eastern on...